SouthState Corp’s Sarepta Therapeutics SRPT Stock Holding History

SouthState Corp’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30	Closed	-$653	–	1369
2026 Q1	$653	Hold	30	–	–	﹤0.01%	1132
2025 Q4	$646	Sell	30 -30	-50%	-$632	﹤0.01%	1191
2025 Q3	$1.16K	Buy	60 +45	+300%	+$802	﹤0.01%	1032
2025 Q2	$257	Buy	15 +10	+200%	+$427	﹤0.01%	1527
2025 Q1	$320	Buy	+5	New	+$526	﹤0.01%	1609

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SouthState Corp's SRPT Position: Q2 2026 in Review

SouthState Corp sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 30 shares — an estimated $653 sold.

SouthState Corp first reported a position in SRPT in Q1 2025 and held it in 5 quarters. The position peaked at $1.16K in Q3 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

SouthState Corp reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
SouthState Corp sold 30 Sarepta Therapeutics shares in Q2 2026, an estimated $653.
SouthState Corp first reported a position in Sarepta Therapeutics in Q1 2025 and held it in 5 quarters.
SouthState Corp's Sarepta Therapeutics position peaked at $1.16K in Q3 2025.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.